Compare ENGN & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENGN | CODA |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Machinery/Components |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.2M | 94.1M |
| IPO Year | 2023 | 2007 |
| Metric | ENGN | CODA |
|---|---|---|
| Price | $1.95 | $8.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $4.29 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.5M | 80.7K |
| Earning Date | 12-21-2026 | 09-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.85 | 15.62 |
| EPS | N/A | ★ 0.36 |
| Revenue | N/A | ★ $20,316,161.00 |
| Revenue This Year | N/A | $9.92 |
| Revenue Next Year | N/A | $17.26 |
| P/E Ratio | ★ N/A | $23.94 |
| Revenue Growth | N/A | ★ 4.98 |
| 52 Week Low | $1.40 | $7.80 |
| 52 Week High | $12.25 | $18.00 |
| Indicator | ENGN | CODA |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 35.79 |
| Support Level | $1.61 | $7.97 |
| Resistance Level | $8.93 | $10.66 |
| Average True Range (ATR) | 0.18 | 0.46 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 47.17 | 23.30 |
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.